CHK1 inhibitors have the potential to enhance DNA damage effects, and preliminary preclinical data suggest that CHK1 represents a promising target for small-cell lung cancer (SCLC), particularly in tumors exhibiting cMYC protein overexpression [123]. Here, MYC is linked to small cell lung carcinoma.